Instructions
Select a story from the list below.
You will have the option to generate a social media post that conveys algorithmic dissentiment from that story.
Select a news article from below to generate a social media post.
| Article Title | Sentiment | Date | Summary | Stock | Id | Author |
|---|---|---|---|---|---|---|
| Article Title | Sentiment | Date | ||||
| A drug giant just got fined £37 million for 'illegal behaviour' | -10 | 2016-02-12 08:14:37+00 | The CMA has also fined the two companies that settled with GSK £1.5 million and £5.8 million, taking the total fines to £45 million. Cracking down on these practices is essential to protect consumers, to encourage legitimate business activity that such practices stifle, and to stimulate innovation and growth. GSK reached out of court settlements with the two companies hoping to introduce generic versions of the drug, delaying the launch of cheaper alternatives until late 2003. This investigation shows our determination to take enforcement action against illegal anti-competitive practices in sectors big and small. NOW WATCH: The surprising things that cost more than gas right nowFollow Business Insider Australia on Facebook, Twitter, and LinkedIn | GSK | {"Oscar Williams-grut"} | 849 |
| GlaxoSmithKline Fined $53 Million in Generic Drug Delay Ruling | -18 | None | ENLARGE The U.K.’s competition regulator has fined U.K. pharmaceutical company GlaxoSmithKline PLC, whose headquarters are shown in London, in this July 29, 2013 photo. Glaxo challenged these pharmaceutical companies, alleging that their generic products would infringe its patents, and started litigation proceedings against them. pharmaceutical company GlaxoSmithKline PLC has been fined £37.6 million ($53.7 million) by the U.K.’s Competition and Markets Authority for trying to delay the potential entry of competitors into the U.K. generic-drugs market for antidepressant drug paroxetine. The CMA on Friday also imposed fines on Generics and Alpharma of £5.84 million and £1.54 million, respectively. In 2001, a number of pharmaceutical companies, including Generics (U.K.) Ltd. and Alpharma Ltd., were trying to enter the U.K. market for paroxetine with a generic version. | GSK | {"Ian Walker Wsj Com","Ian Walker"} | 73 |
| GlaxoSmithKline fined $3bn after bribing doctors to increase drugs sales | -13 | 2012-07-03 00:00:00 | The pharmaceutical group GlaxoSmithKline has been fined $3bn (£1.9bn) after admitting bribing doctors and encouraging the prescription of unsuitable antidepressants to children. At the event, the then chief executive, Jean-Pierre Garnier, said: "What is the number one reason why you should love to be a GSK sales rep? The company admitted corporate misconduct over the antidepressants Paxil and Wellbutrin and asthma drug Advair. Avandia has made $10.4bn in sales, Paxil took $11.6bn, and Wellbutrin sales were $5.9bn during the years covered by the settlement, according to IMS Health, a data group that consults for drug makers. The drug was launched to sales representatives in Las Vegas using images of slot machines, emphasising the bonuses they could make through sales. | GSK | {"Simon Neville"} | 75 |
| GlaxoSmithKline to Pay $20 Million to Settle SEC Bribery Probe | -19 | None | Glaxo entered into the SEC agreement without confirming or denying the charges, the U.S. agency said in its statement. ENLARGE Photo: ReutersGlaxoSmithKline GSK 1.38 % PLC agreed to pay $20 million to settle charges that the drugmaker’s Chinese subsidiaries engaged in bribery schemes to increase sales in the Asian country, the Securities and Exchange Commission said Friday. “The SEC and DOJ investigations were initiated as part of an industry-wide inquiry in 2010.”A Justice Department spokesman declined to comment. Five of the company’s managers, including Mark Reilly, its former top China executive, were also convicted of bribery-related charges and received suspended prison sentences. The SEC alleged that between 2010 and 2013, GlaxoSmithKline’s subsidiary and a China-based joint-venture violated the Foreign Corrupt Practices Act by providing inappropriate gifts to foreign officials, including health-care professionals. | GSK | {"Ezequiel Minaya Wsj Com","Zeke Minaya","Ezequiel Minaya"} | 401 |
| GlaxoSmithKline fined $490m by China for bribery | -19 | None | Image copyright AFP Image caption GSK is one of the world's biggest drug producers but has come under scrutiny in ChinaChina has fined UK pharmaceuticals firm GlaxoSmithKline $490m (£297m) after a court found it guilty of bribery. The court gave GSK's former head of Chinese operations, Mark Reilly, a suspended three-year prison sentence and he is set to be deported. GSK has been in China for close to a hundred years and we remain fully committed to the country and its people," he said. The guilty verdict was delivered after a one-day trial at a court in Changsha, according to the Xinhua news agency. The record penalty follows allegations the drug giant paid out bribes to doctors and hospitals in order to have their products promoted. | GSK | {} | 74 |
| GlaxoSmithKline Accused of Corruption by China | -43 | 2013-07-12 00:00:00 | SHANGHAI — Chinese investigators said Thursday that executives from GlaxoSmithKline, the British drug giant, had admitted to using bribes, kickbacks and other fraudulent means to bolster drug sales in China. In the case of GlaxoSmithKline, Chinese investigators seemed to have moved with lightning speed, detaining workers, raiding offices in various cities and then publicizing their findings Thursday. We have done this in China and found no evidence of bribery or corruption of doctors or government officials. The authorities said that to “open the sales channel and increase prices” in China, GlaxoSmithKline, also called GSK, had bribed or paid off a wide range of people who could aid the company’s sales operations. Among other things, the China subsidiary of GlaxoSmithKline “committed crimes” by writing special bills related to the value-added tax and issued fake invoices through travel agencies, officials said. | GSK | {"David Barboza"} | 885 |
| GlaxoSmithKline accused of bribing doctors in Poland | -50 | 2014-04-14 00:00:00 | GlaxoSmithKline, the British drug company embroiled in bribery scandals in China and Iraq, has been accused of bribing doctors in Poland in the latest corruption furore to hit the business. In 2012, GSK paid a record $3bn (£1.9bn) in fines to settle claims that bribed US doctors into prescribing antidepressants for non-approved uses. Poland's fraud squad, the central anti-corruption bureau, on Monday said 13 people had been charged in connection with allegations of doctors being bribed to promote GSK's asthma drug Seretide. In return for the financial gains the doctors would favour the product proposed by the pharmaceutical company and they prescribed that medicine. In December, Witty promised that GSK would stop making any payments to doctors. | GSK | {"Rupert Neate"} | 886 |
| Infection arcs across GlaxoSmithKline's China network in bribery probe | -46 | 2013-07-25 00:00:00 | As China's investigation into GSK expands, the firm's profits from the crucial emerging growth market are expected to take a hit. Chinese authorities have barred GSK China's Vice President for Finance, British national Steve Nechelput, from leaving the country since late June. Chinese state television also broadcast an apparent confession by Liang Hong . China's investigation could expose the company to legal action in the U.K., and possibly the United States, under laws relating to the bribery of foreign public officials. As Chinese authorities and GlaxoSmithKline reveal new information, here is an overview of the probe, the parties involved and the potential penalties. | GSK | {"For Cnn","Ramy Inocencio"} | 647 |
| China Fines GlaxoSmithKline Nearly $500 Million in Bribery Case | -66 | 2014-09-20 00:00:00 | The Glaxo case showed that “an open China is not a lawless one,” Xinhua, the official news agency, said in a commentary. Many global drug makers used the same Shanghai travel agency that the authorities in the Glaxo case said had altered corporate travel expenses to pay cash bribes. The verdict indicated that Mr. Reilly could be promptly deported. ChinaWhys, which specialized in due diligence work, completed an inconclusive preliminary report on the sex video of Mr. Reilly by June 2013 and suggested continuing the inquiry. The Glaxo case — and sizable fine — represents a setback for the company. | GSK | {"Keith Bradsher","Chris Buckley"} | 1128 |